The maternal & newborn mortality rate is in Indonesia still a high and serious problem faced by all the healthcare stakeholders. Many efforts have been done and explored to reduce the mortality rate. Akademi Ilmu Pengetahuan Indonesia (AIPI) – a government organization who leads the knowledge, science & technology authorities in Indonesia, with JPHIEGO – an international healthcare service organization specializes in mothers & newborn health, conducted an Evidence Summit event in 2017, supported by USAID. The Evidence Summit’s objective is the convene all the stakeholders in Maternal & Newborn health to curate and collaborate all the research data or evidence in order to provide recommendations for Government’s policy to reduce the maternal & newborn mortality rate.
The Evidence Summit’s objective is the convene all the stakeholders in Maternal & Newborn health to curate and collaborate all the research data or evidence in order to provide recommendations for Government’s policy to reduce the maternal & newborn mortality rate. In one of the Evidence Summit series, AIPI convened all the stakeholders coming from NGOs, Academics, Research Institutions, Private sectors, Donor / Aid Agencies, and many others to share and present any actual data.
Innovesia was invited to share about how we can use an open innovation & open collaboration approach to accelerate the evidence by opening our mindset, people, resources and data among the stakeholders. We shared about why Open Innovation & Collaboration is a fit approach for the diverse background of stakeholders. We gave examples on the open innovation practices in the healthcare industry such as in Pharmaceutical. In pharma industry, open innovation approach has ignited a new way of optimizing company’s research & development (R&D) by opening their clinical trial data and sharing it with external parties such as academic scientists or other research institutions, to contribute any relevant evidences. Previously Pharma companies spent billions of dollars for new product’s R&D, using internal R&D capabilities and resources. Now, this approach has given a significant acceleration in the drug’s discovery pathway and development phase, and lower the R&D cost.